Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
Master of Business Administration (M.B.A.)
Doctor of Medicine (M.D.)
B.S.
Total Funding: $260M
Total Funding: $170M
Total Funding: $75M
Total Funding: $75M
Total Funding: $32M
Total Funding: $150M
Total Funding: $110M
Total Funding: $420M
Total Funding: $110M
Total Funding: $140M
2015
2015
venBio is a life science venture capital firm that focuses on novel therapeutics for unmet medical needs. Since inception in 2011, venBio has raised nearly $1.5 billion in capital commitments and led investment rounds in 35+ companies, including: Labrys Biologics (acquired by Teva); ALX Oncology (NASDAQ: ALXO); Aragon Pharmaceuticals (acquired by Johnson & Johnson); Seragon Pharmaceuticals (acquired by Roche); Aurinia Pharmaceuticals (NASDAQ: AUPH); Apellis Pharmaceuticals (NASDAQ: APLS); Turning Point Therapeutics (NASDAQ: TPTX, acquired by BMS); Precision Biosciences (NASDAQ: DTIL); Akero Therapeutics (NASDAQ: AKRO); Harmony Biosciences (NASDAQ: HRMY); Pharvaris (NASDAQ: PHVS); Ventyx Biosciences (NASDAQ: VTYX); CinCor Pharma (NASDAQ: CINC, acquired by AstraZeneca), and RayzeBio (NASDAQ: RYZB, acquired by BMS).
2023
2022
2022
2021
2021
2021
2017
2020 - 2023
2020 - 2023
IPO in September 2023 (NASDAQ: RYZB) Acquired by Bristol Myers Squibb in December 2023 for $4.1B
2021 - 2023
2021 - 2023
IPO in October 2021 (NASDAQ: VTYX)
2017 - 2020
2017 - 2020
IPO in August 2020 (NASDAQ: HRMY) FDA approvals for Wakix in Aug 2019, Oct 2020, and Jun 2024.
2018 - 2019
2018 - 2019
IPO in June 2019 (NASDAQ: AKRO)